Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.
Akebia Therapeutics (AKBA) ha annunciato tre prossime presentazioni poster al 62° Congresso della European Renal Association 2025, che si terrà dal 4 al 7 giugno a Vienna. Le presentazioni si concentreranno sui dati clinici di vadadustat, il loro trattamento per l'anemia correlata alla CKD. Tra le presentazioni principali: un'analisi della sicurezza cardiovascolare di vadadustat nei pazienti in dialisi presentata dal Dr. Glenn Chertow, uno studio sulla combinazione di vadadustat con citrato ferrico, e dati real-world che confrontano gli inibitori HIF-PH con gli ESA in pazienti con CKD non in dialisi, basati su uno studio di un database giapponese.
Akebia Therapeutics (AKBA) anunció tres próximas presentaciones en formato póster en el 62º Congreso de la Asociación Renal Europea 2025, que se celebrará del 4 al 7 de junio en Viena. Las presentaciones se centrarán en datos clínicos sobre vadadustat, su tratamiento para la anemia relacionada con la ERC. Las presentaciones clave incluyen: un análisis de seguridad cardiovascular de vadadustat en pacientes en diálisis presentado por el Dr. Glenn Chertow, un estudio sobre la combinación de vadadustat con citrato férrico, y datos del mundo real que comparan inhibidores HIF-PH con ESA en pacientes con ERC no en diálisis, provenientes de un estudio con base de datos japonesa.
Akebia Therapeutics (AKBA)는 2025년 6월 4일부터 7일까지 비엔나에서 열리는 제62회 유럽 신장학회 총회에서 세 건의 포스터 발표를 예정했다고 발표했습니다. 이번 발표들은 만성 신장병(CKD) 관련 빈혈 치료제인 바다두스타트의 임상 데이터를 중심으로 진행됩니다. 주요 발표 내용은 투석 환자에서 바다두스타트의 심혈관 안전성 분석(글렌 처토 박사 발표), 바다두스타트와 페릭 시트레이트 병용 연구, 일본 데이터베이스 연구를 통한 비투석 CKD 환자에서 HIF-PH 억제제와 ESA 비교 실제 데이터입니다.
Akebia Therapeutics (AKBA) a annoncé trois prochaines présentations sous forme de posters lors du 62e Congrès de l'European Renal Association 2025, qui se tiendra du 4 au 7 juin à Vienne. Les présentations porteront sur les données cliniques de vadadustat, leur traitement de l'anémie liée à la maladie rénale chronique (CKD). Les présentations clés incluent : une analyse de la sécurité cardiovasculaire de vadadustat chez les patients en dialyse présentée par le Dr Glenn Chertow, une étude sur la combinaison de vadadustat avec le citrate ferrique, ainsi que des données en conditions réelles comparant les inhibiteurs HIF-PH aux ESA chez les patients CKD non dialysés, issues d'une étude basée sur une base de données japonaise.
Akebia Therapeutics (AKBA) kündigte drei bevorstehende Posterpräsentationen auf dem 62. Kongress der European Renal Association 2025 an, der vom 4. bis 7. Juni in Wien stattfindet. Die Präsentationen konzentrieren sich auf klinische Daten zu Vadadustat, ihrer Behandlung der CKD-bedingten Anämie. Zu den wichtigsten Präsentationen gehören: eine Analyse der kardiovaskulären Sicherheit von Vadadustat bei Dialysepatienten, vorgestellt von Dr. Glenn Chertow, eine Studie zur Kombination von Vadadustat mit Eisen(III)-citrat sowie Real-World-Daten, die HIF-PH-Inhibitoren mit ESAs bei nicht dialysepflichtigen CKD-Patienten anhand einer japanischen Datenbankstudie vergleichen.
- None.
- None.
Vadadustat clinical data on display for nephrologists and healthcare providers
CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced it will present data at the 62nd European Renal Association (ERA) Congress on June 4-7, 2025, both virtually and live in Vienna.
Akebia-supported presentations at ERA Congress 2025:
- A Win-Ratio Analysis of the Cardiovascular Safety of Vadadustat in Patients with CKD-Related Anemia Undergoing Dialysis
Free Communication 15: Novel CKD Treatments Beyond the Pillars
Abstract No. 3359
Dr. Glenn Chertow to present on Friday, June 6 at 8:15 am CEST
- Real-World Use of HIF-PH Inhibitors and ESAs in Non-Dialysis-Dependent CKD with Anemia: Insights from a Japanese Database study
E-Poster No. 1325
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
What data will Akebia Therapeutics (AKBA) present at ERA Congress 2025?
When and where is the ERA Congress 2025 where AKBA will present?
Who will present the cardiovascular safety analysis for AKBA's vadadustat at ERA 2025?
What is the purpose of Akebia Therapeutics' vadadustat presentations at ERA 2025?
